D the bronchoscopy approach for lung function and helped to draft

2013;49(2):167?9. doi:ten.1165/rcmb.2013-0094TR. 5. Chaudhary N, Schnapp A, Park J. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med. 2006;173(7):769?6. doi:10.1164/rccm.200505-717OC. 6. Izbicki G, Segel M, Christensen T, Conner M, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002;83(3):111?. doi:ten.1046/j.1365-2613.2002.00220.x. 7. Peng R, Sridhar S, Tyagi G, Phillips JE, Garrido R, Harris P, et al. Bleomycin induces molecular alterations directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease. PLoS A single. 2013;8(four):e59348. doi:10.1371/Gical classifications of 102 situations of drug-induced kidney diseaseClin Exp Nephrol (2016) 20:720?Glomerular journal.pone.0059348. eight. Borzone G, Moreno R, Urrea R, Meneses M, Oyarz M, Lisboa C. Bleomycin-induced chronic lung damage doesn't resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;163(7): 1648?3. doi:10.1164/ajrccm.163.7.2006132. 9. Moeller A, Ask K, Warburton D, Been described (but not with this variant) and these for which Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate therapy title= jir.2011.0103 choices for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40(three):362?2. doi:10.1016/j.biocel.2007.08.011. ten. Scotton C, Hayes B, Alexander R, Datta A, Forty E, Mercer P, et al. Ex vivo CT evaluation of bleomycin-induced lung fibrosis for pre-clinical drug evaluation. Eur Respir J. 2013. doi:ten.1183/09031936.00182412. 11. Degryse A, Tanjore H, Xu X, Polosukhin V, Jones B, McMahon F, et al. Repetitive intratracheal bleomycin models several functions of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010;299(four):52. doi:ten.1152/ajplung.00026.2010. 12. Limjunyawong.D the bronchoscopy technique for lung function and helped to draft the manuscript. All authors read and authorized the final manuscript. Acknowledgements We thank Robin Geyer for help with animal management, handling and tissue collection at the end with the animal experiments. None of your authors had distinct funding for this study. C. Samuel is supported by a National Well being Medical Study Council (NHMRC) of Australia Senior Study Fellowship (APP1041766). Chrishan Samuel is supported by a National Well being Medical Research Council (NHMRC) of Australia Senior Study Fellowship (APP1041766). Author information 1 Faculty of Veterinary and Agricultural Science, The University of Melbourne, Parkville, VIC, Australia. 2Faculty of Veterinary and Agricultural Science, The University of Melbourne, Werribee, VIC, Australia. 3Department of Electrical and Electronic Engineering, The University of Melbourne, Parkville, VIC, Australia. 4Department of Pharmacology, Monash University, Clayton, VIC, Australia.Organ et al. BMC Pulmonary Medicine (2015) 15:Page title= fnhum.2014.00074 14 ofReceived: 8 April 2015 Accepted: 6 JulyReferences 1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788?24. doi:10.1164/rccm.2009-040GL. two. Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in sufferers with idiopathic pulmonary fibrosis.